• NICE rules Afinitor ‘too expensive’
  
  08 Feb 2010
  NICE has ruled that it is unable to recommend Novartis’ everolimus (Afinitor) for the second line treatment of advanced renal cell carcinoma, due to doubts about its ability to extend life. Read More
  
  
• Stelara approved for use in Scotland
  
  08 Feb 2010
  Stelara (ustekinumab) has been accepted by the Scottish Medicines Consortium (SMC) for restricted use in the treatment of moderate to severe plaque psoriasis. Read More
  
  
• Sprycel and Tasigna ‘not recommended’ for imatinib intolerant patients
  
  08 Feb 2010
  NICE has updated its draft guidance on the use of Bristol Myers-Squibb’s dasatinib (Sprycel) and Novartis’ nilotinib (Tasigna) for chronic myeloid leukaemia. Read More
  
  
• Orencia approved for EU pJIA patients
  
  05 Feb 2010
  Bristol-Myers Squibb’s Orencia (abatacept) has secured marketing approval in the EU to treat paediatric patients. Read More
  
  
• Read more pharma jobs news >>

News powered by Pharmaceutical Field (Pf)